ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 97 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is 1.27 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $57,000 | -51.7% | 1,114 | -23.6% | 0.00% | – |
Q1 2018 | $118,000 | +413.0% | 1,458 | +125.0% | 0.00% | – |
Q3 2015 | $23,000 | -14.8% | 648 | +6.4% | 0.00% | – |
Q2 2015 | $27,000 | -95.4% | 609 | -94.8% | 0.00% | -100.0% |
Q4 2014 | $591,000 | +620.7% | 11,613 | +461.6% | 0.00% | – |
Q3 2014 | $82,000 | -14.6% | 2,068 | -7.2% | 0.00% | – |
Q2 2014 | $96,000 | -5.0% | 2,228 | -11.8% | 0.00% | – |
Q1 2014 | $101,000 | -67.4% | 2,525 | -81.4% | 0.00% | -100.0% |
Q3 2013 | $310,000 | -23.8% | 13,546 | -41.0% | 0.00% | 0.0% |
Q2 2013 | $407,000 | – | 22,972 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |